| # | Title | Journal | Year | Citations |
|---|
| 1 | The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes | Blood | 2009 | 3,864 |
| 2 | International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma | Lancet Oncology, The | 2014 | 3,343 |
| 3 | Improved survival in multiple myeloma and the impact of novel therapies | Blood | 2008 | 2,022 |
| 4 | Changes in Burnout and Satisfaction With Work-Life Balance in Physicians and the General US Working Population Between 2011 and 2014 | Mayo Clinic Proceedings | 2015 | 1,982 |
| 5 | International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma | Lancet Oncology, The | 2016 | 1,866 |
| 6 | Chimeric antigen receptor T-cell therapy — assessment and management of toxicities | Nature Reviews Clinical Oncology | 2018 | 1,659 |
| 7 | Burnout and Medical Errors Among American Surgeons | Annals of Surgery | 2010 | 1,522 |
| 8 | Interventions to prevent and reduce physician burnout: a systematic review and meta-analysis | Lancet, The | 2016 | 1,498 |
| 9 | Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma | Journal of Clinical Oncology | 2006 | 1,203 |
| 10 | Prevalence of Monoclonal Gammopathy of Undetermined Significance | New England Journal of Medicine | 2006 | 1,135 |
| 11 | Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients | Leukemia | 2014 | 1,128 |
| 12 | The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms | Leukemia | 2022 | 1,023 |
| 13 | Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma | Leukemia | 2009 | 1,000 |
| 14 | MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients | Blood | 2006 | 963 |
| 15 | Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma | Nature Medicine | 2015 | 927 |
| 16 | Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms | Leukemia | 2008 | 908 |
| 17 | Multiple myeloma | Nature Reviews Disease Primers | 2017 | 812 |
| 18 | A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) | Blood | 2010 | 805 |
| 19 | Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group | Journal of Clinical Oncology | 2006 | 802 |
| 20 | Multiple myeloma | Blood | 2008 | 759 |
| 21 | Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma | New England Journal of Medicine | 2007 | 740 |
| 22 | Relationship Between Clerical Burden and Characteristics of the Electronic Environment With Physician Burnout and Professional Satisfaction | Mayo Clinic Proceedings | 2016 | 739 |
| 23 | Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease | EBioMedicine | 2019 | 697 |
| 24 | Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial | Lancet, The | 2017 | 684 |
| 25 | Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management | Leukemia | 2010 | 677 |
| 26 | Increased Prevalence and Mortality in Undiagnosed Celiac Disease | Gastroenterology | 2009 | 675 |
| 27 | Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial | Blood | 2007 | 655 |
| 28 | Mutations and prognosis in primary myelofibrosis | Leukemia | 2013 | 653 |
| 29 | Genetics and Cytogenetics of Multiple Myeloma | Cancer Research | 2004 | 642 |
| 30 | Myelodysplastic Syndromes | New England Journal of Medicine | 2009 | 614 |
| 31 | Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma | Blood | 2005 | 604 |
| 32 | Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report | Blood | 2015 | 586 |
| 33 | Clonal competition with alternating dominance in multiple myeloma | Blood | 2012 | 575 |
| 34 | Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis | Blood | 2014 | 575 |
| 35 | Intervention to Promote Physician Well-being, Job Satisfaction, and Professionalism | JAMA Internal Medicine | 2014 | 559 |
| 36 | Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance | Blood | 2005 | 557 |
| 37 | Rituximab for IgG4-related disease: a prospective, open-label trial | Annals of the Rheumatic Diseases | 2015 | 533 |
| 38 | Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer | Journal of Clinical Oncology | 2005 | 526 |
| 39 | Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials | JAMA Oncology | 2019 | 526 |
| 40 | Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management | American Journal of Hematology | 2020 | 507 |
| 41 | Single Item Measures of Emotional Exhaustion and Depersonalization Are Useful for Assessing Burnout in Medical Professionals | Journal of General Internal Medicine | 2009 | 504 |
| 42 | Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders | Nature Reviews Cancer | 2007 | 503 |
| 43 | IMWG consensus on risk stratification in multiple myeloma | Leukemia | 2014 | 500 |
| 44 | Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 | Leukemia | 2010 | 499 |
| 45 | Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors | Blood | 2009 | 484 |
| 46 | Multiple Myeloma: Diagnosis and Treatment | Mayo Clinic Proceedings | 2016 | 473 |
| 47 | CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons | Leukemia | 2014 | 465 |
| 48 | Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System | Journal of the American College of Cardiology | 2016 | 460 |
| 49 | Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant | Blood | 2012 | 447 |
| 50 | Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013 | Mayo Clinic Proceedings | 2013 | 440 |
